Disposition of patients. A total of 288 patients were enrolled in part 2, including 200 imatinib-resistant patients and 88 imatinib-intolerant patients. *AEs leading to withdrawal in 2 or more imatinib-resistant patients included thrombocytopenia (n = 6), aspartate aminotransferase elevation (n = 4), alanine aminotransferase elevation (n = 3), diarrhea (n = 3), neutropenia (n = 2), anemia (n = 2), leukopenia (n = 2), and vomiting (n = 2). AEs leading to withdrawal in 2 or more imatinib-intolerant patients included thrombocytopenia (n = 8), diarrhea (n = 3), alanine aminotransferase elevation (n = 3), aspartate aminotransferase elevation (n = 2), dyspnea (n = 2), neutropenia (n = 2), pancytopenia (n = 2), and rash (n = 2).